TargED Biopharmaceuticals

TargED Biopharmaceuticals is a clinical-stage biotechnology company based in Utrecht, Netherlands.

Founded in July 2020 as a spin-off from the University Medical Center Utrecht, TargED focuses on developing innovative biological drugs to enhance the treatment of thrombosis, which includes blood clots. The company utilizes a proprietary technology called Targeted Enzyme Delivery, employing small antibody fragments to deliver clot-dissolving enzymes directly to thrombus sites, allowing for precise treatment with reduced side effects. The lead compound, TGD001 (also known as MICROLYSE), targets proteins involved in various thrombotic disorders, including Immune Thrombotic Thrombocytopenic Purpura (iTTP) and Acute Ischemic Stroke (AIS). TargED aims to address critical unmet needs in thrombotic disease treatment and has raised over €45 million in funding to support its mission. The company is committed to advancing therapies for patients suffering from thrombosis and is actively working towards securing market authorization for its innovative solutions.